---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-286419"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:45:38.076541+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# TuHURA provides pro forma statements for Kineta merger, closed June 30, 2025

## Summary
- Pro forma combined statements for nine months ended Sept 30, 2025 and year ended Dec 31, 2024.
- Kineta acquisition accounted for as business combination; TuHURA as acquirer with 92.4% ownership post-merger.
- Pro forma adjustments eliminate pre-merger intercompany transactions and financing costs.
- TuHURA advancing Kineta's VISTA-101 trial; REM-001 study underway with CVR milestone by Dec 31, 2025.
- Historical financials of TuHURA remain the consolidated financial statements post-merger.

## SEC filing metadata
- accession: 0001193125-25-286419
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000119312525286419/0001193125-25-286419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000119312525286419/d851083d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-286419
- JSON: https://secwatch.observer/filing/0001193125-25-286419.json
- Plain text: https://secwatch.observer/filing/0001193125-25-286419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.